Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

44,166 common shares were sold directly for approximately $758,000 at a weighted average price of $13.26 per share across April 9, 10, and 13, 2026. The article is a factual insider sale disclosure with no accompanying operating update or broader business catalyst. Market impact is likely limited unless the transaction signals a larger insider trend.

Analysis

44,166 common shares were sold directly for approximately $758,000 at a weighted average price of $13.26 per share across April 9, 10, and 13, 2026. The article is a factual insider sale disclosure with no accompanying operating update or broader business catalyst. Market impact is likely limited unless the transaction signals a larger insider trend.